Application of T6 Heat Treatment on the AlSi9Cu3 (Fe) Casting Alloy and the Effect of Copper Content

AlSi9Cu3 (Fe) foundry alloy is commonly used to produce components by High Pressure Die Casting (HPDC) for automotive and electrical industries. Mostly for cost reasons, the Cu content is held at the minimum of the compositional range foreseen by the standards. The strength of the metal is then quite low and therefore the components are used only in low or non-stressed applications. The experimental results of the present paper show that in the as cast temper, the percentage of Cu has little effect on strength. It is suggested that alternative alloys for HPDC with lower or no Cu content be adopted for non-stressed components. In the last 15 years, it has been demonstrated that Al-Si-Cu alloys for HPDC may successfully heat-treated by unconventional T6 without causing surface blistering or dimensional instability. Despite the new opportunities, there have been few industrial applications. Instead, the present authors believe possible new technological outcomes for unconventional T6, and have therefore experimented with the AlSi9Cu3 (Fe) alloy with different Cu contents. By using SEM-EDX microanalysis to get Cu composition maps in the alloy microstructure, a T6 heat treatment with lower solubilization temperature and shorter soaking time to avoiding blistering has been identified. Tensile test confirmed the effectiveness of unconventional T6 and showed a strong increase in the elastic limit of the material. The results also show that the best effect is obtained by increasing the Cu content as much as possible. It is therefore possible to produce components for highly stressed structural applications in T6 treated AlSi9Cu3 (Fe) alloy

The behaviour of REEs in Thailand's Mae Klong estuary: Suggestions from the Y/Ho ratios and lanthanide tetrad effects

The concentrations of Rare Earth Elements and yttrium (REY) were measured in dissolved phase, in suspended particulate matter (SPM) and in sediments in seven sampling stations in the Mae Klong estuarine system (Inner Thailand Gulf) in order to study their behaviour and distribution pattern. The analysed samples generally show high Rare Earth Element (REE) content in the dissolved phase, with high Medium Rare Earth Elements (MREEs) and Yenrichments in the shale-normalized pattern (versus PAAS). These chemical features are interpreted in terms of direct influences of weathering processes of REE-rich minerals (e.g., phosphates), which abundantly out-crop in the Mae Klong watershed. These large MREE enrichments also suggest that dissolved sulphate complexes play an important role in the dissolved REE fate close to the marine coastal system. The shale normalized REEs and Y/Ho ratios additionally indicate a direct REY co-precipitation with Fe-oxyhydroxides along the river path and consequent adsorption, as coating, onto FeOOH surfaces. The REY behaviour in SPM appears strongly influenced by Al, Fe and Mn content, suggesting that the formation of an authigenic Fe, Mn oxyhydroxides and aluminosilicate particulate leads to REY adsorption and/or co-precipitation. The observed variations in the Y/Ho ratios suggest that different YeHo fractionation processes take place in the studied estuarine system. Strong similarities among chondrite-normalized REE patterns in both sediments and granitic rocks out-cropping in the surrounding regions suggest a generic relationship between the two groups of materials

Rare-earth elements and yttrium distributions in mangrove coastal water systems: The western Gulf of Thailand

The concentration of rare-earth elements and yttrium (REY) was investigated in dissolved phase, suspended particulate matter, and seafloor sediments of the western coastal area of the Gulf of Thailand. The samples show Eu and Gd positive anomalies in the shale-normalized REY patterns, especially in the suspended particulate matter. On the other hand, a very high REE content was detected in the coastal waters, probably due to the weathering produced by the Mae Klong river waters on rare-earth element (REE)-rich accessory minerals coming from terrains and mineral deposits cropping out in the studied area. The shale-normalized patterns of yttrium and REE estimated for the dissolved phase show an enrichment of medium rare-earth elements (MREE), characteristic of extensive water–rock interactions and weathering occurring in the continental environment. The REE concentrations of suspended particulate, normalized to the REE concentrations in each sediment sampled from the tidal flat, show the same behaviour of the experimentally determined apparent REE bulk distribution coefficients 1 for pH values ranging from about 5.5 to 6.2. Since the REY concentration of the water masses is controlled by the oceanographic features of the studied area, riverine inputs, and ionic straight, we suppose that the dissolved phase represents a mix of truly dissolved and colloidal pool (<0.2 μm) in which REY were enriched during the rock–water interactions of continental environment. In the estuarine system, the salt-induced coagulation of colloidal pool takes place and an authigenic fraction of suspended matter is formed, assuming the typical REE behaviour due to rock–water interactions

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

International audienc

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

Abstract: Background: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)\u2013defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). Methods: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. Results: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52\u20131.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. Conclusions: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.Abstract: BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). METHODS: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. RESULTS: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52-1.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. CONCLUSIONS: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs